"Detection, measurement, and imaging of cells such as cancer and other biologic substances using targeted nanoparticles and magnetic properties thereof."
NEW YORK--Manhattan Scientifics, Inc. announced today that its Senior Scientific, LLC unit, a nanobiotechnology company for the early detection and localization of cancer and other human diseases, has been granted an additional United States Patent for its MRX™ cancer detection technology. U.S. Patent No. US 9,095,270 B2 entitled "Detection, measurement, and imaging of cells such as cancer and other biologic substances using targeted nanoparticles and magnetic properties thereof." The patent provides a method as well as an apparatus for detecting and measuring cancer cells, using magnetic nanoparticles.
Bob Proulx, COO and President of Senior Scientific said, "The issuance of this patent is an important milestone strengthening the intellectual property portfolio for our core business. We can now continue to pursue product development and commercialization strategies knowing that we and our partners have a strong patent position as we apply our magnetic relaxometry technology for in vivo diagnostic applications."
Manhattan Scientifics Inc. is located in New Mexico, New York and Montreal. It is focused on technology transfer and commercialization of transformative technologies in the nano medicine space. The company is presently developing commercial medical prosthetics applications for its ultra-fine grain metals and plans to commercialize the cancer research work and nano medical applications developed by Senior Scientific LLC, a unit of the Company.
This press release contains forward-looking statements, which are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such forward-looking statements. Management at Manhattan Scientifics believes that purchase of its shares should be considered to be at the high end of the risk spectrum. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.